How Much Do You Have to Weigh to Get Ozempic?

Last reviewed: June 7, 2026

Last updated: June 7, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

There is no weight requirement for Ozempic, and there is no body mass index criterion anywhere in its label — because Ozempic has no weight-management indication for such a criterion to attach to. The Ozempic prescribing information lists three indications, all in type 2 diabetes: glycemic control as an adjunct to diet and exercise, reduction of major adverse cardiovascular event risk in adults with established cardiovascular disease, and reduction of the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in adults with chronic kidney disease. The BMI thresholds people have in mind belong to a different product.

Why the Question Has No Answer as Asked

Eligibility for a prescription medication is defined by its labeled indication. Ozempic’s indications are all anchored to a diagnosis of type 2 diabetes, so the qualifying criterion is that diagnosis and the associated clinical circumstances — not a number on a scale.

This is not a technicality. A person with type 2 diabetes at any weight may fall inside the Ozempic label; a person with obesity and no diabetes does not, regardless of how high their weight is.

The confusion is understandable, because Ozempic became widely known through weight-loss coverage. But the coverage attached the wrong brand name to the phenomenon.

Where the BMI Thresholds Actually Come From

The weight-management semaglutide product is Wegovy, and its labeled population is adults and pediatric patients aged 12 and older with obesity, or adults with overweight in the presence of at least one weight-related comorbid condition, in combination with a reduced-calorie diet and increased physical activity.

The pivotal trials behind that indication used explicit thresholds. Wegovy Study 2 enrolled patients with obesity defined as body mass index of 30 kg/m² or greater, or with overweight at 27 to 29.9 kg/m² plus at least one weight-related comorbid condition such as treated or untreated dyslipidemia or hypertension. Study 3 enrolled patients with type 2 diabetes and body mass index of at least 27 kg/m².

Those numbers describe Wegovy trial entry criteria. Applying them to Ozempic imports a criterion from a document that does not govern it.

What Ozempic Eligibility Actually Turns On

A diagnosis of type 2 diabetes is the gateway for the glycemic control indication. The cardiovascular indication additionally requires established cardiovascular disease, and the renal indication additionally requires chronic kidney disease. Each is a distinct clinical circumstance documented by a clinician.

Screening then runs through the contraindications and warnings. The label contraindicates use in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, and in patients with serious hypersensitivity to semaglutide or its excipients.

Other history that matters includes pancreatitis, gallbladder disease, diabetic retinopathy — the label notes retinopathy complications reported in a clinical trial and directs monitoring in patients with a history of it — kidney function, severe gastroparesis, and pregnancy planning.

Off-Label Prescribing Is a Different Question

A licensed clinician may prescribe an approved drug outside its labeled indication when they judge it clinically appropriate. That practice is lawful and common across medicine.

It does not change the approval status, it does not create a BMI criterion where the label has none, and it does not obligate an insurer to cover the prescription. It also places the entire judgement on the prescriber, weighing your diagnoses, other medications and risk factors.

The Weight Number That Does Appear in the Labels

Body weight shows up in these documents as a measured outcome, not as an eligibility gate. Wegovy Study 2 recorded a mean baseline body weight of 105.3 kg and mean body mass index of 37.9 kg/m², with mean weight change of −14.9% versus −2.4% with placebo at 68 weeks.

In SURMOUNT-1, 2,539 adults over 72 weeks showed mean weight changes of −15.0%, −19.5% and −20.9% across three tirzepatide doses versus −3.1% with placebo. These describe what happened to participants, not who was allowed in.

The Right Question to Ask Instead

Ask which approved indication your clinical situation maps to. If you have type 2 diabetes, the Ozempic label may be relevant. If your concern is weight, the relevant documents are the Wegovy label, the Zepbound label, or the orforglipron label.

Then ask your prescriber to assess you against that indication and against the contraindications and warnings in the applicable label. That is a determination no article can make, and it is the only one that actually decides the matter.

Where the Weight Question Comes From

The premise behind this question is that access to a medication is rationed by a number, and for some weight-management products that is roughly true. Body mass index thresholds appear in the labeled populations of the weight-management products and in payer criteria built on top of them.

Ozempic simply is not one of those products. Its qualifying condition is a diagnosis, and the clinical circumstances attached to each of its three indications — type 2 diabetes alone for glycemic control, plus established cardiovascular disease for the cardiovascular indication, plus chronic kidney disease for the renal indication.

It is also worth knowing that body mass index has real limitations as a clinical measure. It does not distinguish fat mass from lean mass and performs differently across populations, which is why the labeled populations pair it with comorbid conditions rather than relying on a number alone. Your prescriber assesses the whole picture.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test ($298) to personalize your protocol from day one.

Frequently Asked Questions

What BMI do I need for Ozempic?

None is specified. There is no body mass index criterion anywhere in the Ozempic label, because Ozempic has no weight-management indication. Its three indications are glycemic control in adults with type 2 diabetes, cardiovascular event risk reduction in adults with type 2 diabetes and established cardiovascular disease, and renal and cardiovascular death risk reduction in adults with chronic kidney disease.

Which semaglutide product uses BMI thresholds?

Wegovy. Its labeled population is adults and pediatric patients aged 12 and older with obesity, or adults with overweight plus at least one weight-related comorbid condition. The pivotal trials used body mass index of 30 kg/m2 or greater for obesity and 27 to 29.9 kg/m2 with a comorbid condition such as dyslipidemia or hypertension for overweight.

Can I get Ozempic if I have obesity but not diabetes?

Not within the labeled indications, all of which require type 2 diabetes. A clinician may lawfully prescribe an approved drug off-label when they judge it appropriate, but that does not change the approval status or obligate coverage. The FDA-approved semaglutide product for that clinical situation is Wegovy, which carries weight-management indications.

Does my weight affect the Ozempic dosage?

The label’s dosage instructions are not weight-based. It directs starting at 0.25 mg once weekly, increasing to 0.5 mg after four weeks, and increasing further if additional glycemic control is needed after at least four weeks on the current dosage. Any dosing question about your own regimen belongs with your prescriber and the labeling for the product you were dispensed.

What would actually disqualify me?

The label contraindicates Ozempic in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, and in patients with serious hypersensitivity to semaglutide or any excipient. History of pancreatitis, gallbladder disease, diabetic retinopathy, severe gastroparesis and pregnancy planning all change the clinical assessment as well.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.